Clinical trials: Chemotherapy Induced Thrombocytopenia
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
- Trial name
- NCT03937154
- Testing
- Romiplostim
- Where
- 34 sites in United States, Argentina and 8 more
- Volunteers
- 145 people
- Sponsor
- Amgen
Acute Leukaemia
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
The purpose of this randomized, blinded, placebo-controlled study was to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard…
- Trial name
- NCT01890746
- Testing
- Daunorubicin, Cytarabine, Eltrombopag
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia
A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
This study is a single-arm, exploratory, self-controlled clinical trial for the prevention of thrombocytopenia induced by gemcitabine plus cisplatin in the treatment of nasopharyngeal carcinoma.
- Trial name
- NCT07252375
- Testing
- herombopag olamine tablets
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia
Single Arm Romiplostim to Prevent CIT
The goal of this clinical trial is to to assess the efficacy of romiplostim as a supportive care measure in patients with a new diagnosis of Ewing sarcoma receiving interval-compressed chemotherapy.
- Trial name
- NCT07048249
- Testing
- Romiplostim (AMG-531)
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lymphoma Patients, Thrombocytopenia
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
The purpose of this study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma.
- Trial name
- NCT04673266
- Testing
- Romiplostim
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
- Trial name
- N01-A-PICIT-GT (NCT07586826)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of lymphomas measured by the ability to administer on-time, full-dose chemotherapy.
- Trial name
- NCT03343847
- Testing
- Romiplostim
- Sponsor
- Amgen
Gastrointestinal Cancer, Gastrointestinal Neoplasms
Avatrombopag vs. Placebo for CIT in GI Malignancies
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
- Trial name
- ACT-GI (NCT05772546)
- Testing
- Avatrombopag
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Hanny Al-Samkari, MD
CTIT-Chemotherapy Induced Thrombocytopenia
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
- Trial name
- NCT06440824
- Testing
- Romiplostim N01, Recombinant Human Thrombopoietin
- Volunteers
- 60 people
- Sponsor
- Shandong University
Sarcoma, Soft Tissue, Osteosarcoma
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
The purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. Thrombocytopenia is when there is a low number of platelets in the blood.
- Conditions
- Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue
- Trial name
- NCT01491594
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Chemotherapy-Induced Thrombocytopenia
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Hetrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of solid tumors.
- Trial name
- NCT03976882
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia
The purpose of this study is evaluate the efficacy and safety of eltrombopag as a rescue of isolated chemotherapy-induced thrombocytopenia in patients with solid tumor .
- Trial name
- NCT02093325
- Testing
- Eltrombopag
- Where
- 3 sites in Taiwan
- Volunteers
- 83 people
- Sponsor
- Chang Gung Memorial Hospital
Gastrointestinal Cancer
A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer
This is a prospective, interventional, open-label, single-arm, multicenter pilot study evaluating the safety, tolerability and maximum tolerated dose (MTD) of splenic Selective Internal Radiation Therapy (SIRT) using TheraSphere…
- Trial name
- SPLENIC-SIRT (NCT07575854)
- Testing
- TheraSphere
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Centre Georges Francois Leclerc
Thrombocytopenia
A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with chemotherapy-induced thrombocytopenia (CID).
- Trial name
- NCT06521931
- Testing
- PN20
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Purpura, Thrombocytopaenic, Idiopathic
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems.
- Trial name
- NCT00442871
- Testing
- eltrombopag
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chemotherapy Induced Thrombocytopenia
A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy
The study consists of five sequential periods: Screening (≤ 4 weeks) Correction phase Maintenance phase (first treatment cycle, Cycle 1) Observation phase (second treatment cycle, Cycle 2) Follow-up Eligible subjects are…
- Trial name
- NCT07408648
- Testing
- hetrombopag 7.5 mg orally once daily
- Volunteers
- 244 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Chemotherapy Induced Thrombocytopenia
Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients
Chemotherapy Induced Thrombocytopenia is a common side-effect of bone marrow suppression as a result of a chemotherapy treatment.
- Trial name
- NCT00926354
- Testing
- AS101
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- BioMAS Ltd
Chemotherapy-induced Thrombocytopenia (CIT)
A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Preliminary Efficacy and Pharmacokinetics of SCB-219M in the patients with chemotherapy-induced thrombocytopenia (CIT)
- Trial name
- NCT05426369
- Testing
- Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors
This trial is a single-arm, prospective clinical study aimed at evaluating the efficacy and safety of hetrombopag in preventing chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal tumors.
- Trial name
- NCT07492693
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changhai Hospital
CTIT-Chemotherapy Induced Thrombocytopenia
TPO Combined With TPORA for Solid Tumors Effectiveness of cTit Above Degree II
This study was an open-label, controlled, single-center, prospective phase II trial. In this prospective, real-world study, consecutive patients meeting eligibility criteria will be enrolled and allocated to: Group A (Grade Ⅱ…
- Trial name
- NCT06769685
- Testing
- rhTPO, hypertrombopa
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinhua Central Hospital